CCME Global allots 15,08,42,244 shares; Interlink a subsidiary, CCME UAE an associate
CCME Global · Pharmaceuticals & Biotechnology
Key highlights
- Allotted 15,08,42,244 equity shares of INR 10 each, aggregating to INR 150,84,22,440; paid-up capital rises from 4,52,50,000 to 19,60,92,244 shares.
- 11,25,00,000 shares at par (INR 112,50,00,000) issued to promoters for 45% of CCME UAE, related-party deal; turnover AED 6,90,25,527, net profit AED 43,98,509 for period ended June 30, 2026.
- 2,03,42,244 shares (INR 20,34,22,440) issued for 52% of Interlink, now a subsidiary; turnover AED 70,35,716, net profit AED 5,40,610 for period ended June 30, 2026.
Why it's rated major development: the amount is 98% of market value (50% or more)
Figures checked against the filing by a second AI read, which corrected the first summary. About the business, not the share price.
Original filing
Board Meeting Outcome for Outcome Of The Meeting Of The Preferential Issue Committee Held On October 28, 2026
Read the filing on BSE (PDF) →Companies guiding to strong growth
Ranked by management's own guidance on revenue and margins — not by us.
Electrical Equipment
Sign up free to see all 6 →
See full rankingsRank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
More from CCME Global
- Fundraise / allotmentMajor developmentCCME Global Limited announces allotment of shares for acquisitions and preferential issues
Other fundraise / allotment filings this fortnight
- Clean Max Enviro: Q2 results, NCDs up to Rs 3,000 crore approved, IFSC subsidiary planned
- Lloyds Metals and Energy Limited approves Q2 results, investment, and fundraising plans
- Lloyds Metals approves Q2 results, ₹625 crore TEIL investment and USD 300 million debt
- Mena Mani Industries approves Sept 2026 results, hotel venture and software expansion
- Sat Kartar Life Limited receives NSE approval for 5,50,000 convertible warrants issue
- CL Educate Limited approves ₹140 Cr fund raise and reports Q2 FY27 financials
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Summary written by Arthneeti from the company's filing with the stock exchange; check the original filing for full details. Arthneeti is a research and analytics platform, not a SEBI-registered investment adviser, and nothing here is a recommendation to buy or sell.